A Phase 3, Prospective, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multi-center Study of SC411 for Sickle Cell Disease
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2016
At a glance
- Drugs Docosahexaenoic acid (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Acronyms SCOT
- Sponsors Sancilio & Company
- 07 Jun 2017 Biomarkers information updated
- 19 Dec 2016 According to a Sancilio & Company media release, status changed from not yet recruiting to recruiting.
- 22 Nov 2016 Planned End Date changed from 1 Dec 2017 to 1 Sep 2019.